当前位置：
X-MOL 学术
›
N. Engl. J. Med.
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC
The New England Journal of Medicine ( IF 96.2 ) Pub Date : 2024-06-26 , DOI: 10.1056/nejmoa2403614 Byoung C. Cho 1 , Shun Lu 1 , Enriqueta Felip 1 , Alexander I. Spira 1 , Nicolas Girard 1 , Jong-Seok Lee 1 , Se-Hoon Lee 1 , Yurii Ostapenko 1 , Pongwut Danchaivijitr 1 , Baogang Liu 1 , Adlinda Alip 1 , Ernesto Korbenfeld 1 , Josiane Mourão Dias 1 , Benjamin Besse 1 , Ki-Hyeong Lee 1 , Hailin Xiong 1 , Soon-Hin How 1 , Ying Cheng 1 , Gee-Chen Chang 1 , Hiroshige Yoshioka 1 , James C.-H. Yang 1 , Michael Thomas 1 , Danny Nguyen 1 , Sai-Hong I. Ou 1 , Sanjay Mukhedkar 1 , Kumar Prabhash 1 , Manolo D’Arcangelo 1 , Jorge Alatorre-Alexander 1 , Juan C. Vázquez Limón 1 , Sara Alves 1 , Daniil Stroyakovskiy 1 , Marina Peregudova 1 , Mehmet A.N. Şendur 1 , Ozan Yazici 1 , Raffaele Califano 1 , Vanesa Gutiérrez Calderón 1 , Filippo de Marinis 1 , Antonio Passaro 1 , Sang-We Kim 1 , Shirish M. Gadgeel 1 , John Xie 1 , Tao Sun 1 , Melissa Martinez 1 , Mariah Ennis 1 , Elizabeth Fennema 1 , Mahesh Daksh 1 , Dawn Millington 1 , Isabelle Leconte 1 , Ryota Iwasawa 1 , Patricia Lorenzini 1 , Mahadi Baig 1 , Sujay Shah 1 , Joshua M. Bauml 1 , S. Martin Shreeve 1 , Seema Sethi 1 , Roland E. Knoblauch 1 , Hidetoshi Hayashi 1
The New England Journal of Medicine ( IF 96.2 ) Pub Date : 2024-06-26 , DOI: 10.1056/nejmoa2403614 Byoung C. Cho 1 , Shun Lu 1 , Enriqueta Felip 1 , Alexander I. Spira 1 , Nicolas Girard 1 , Jong-Seok Lee 1 , Se-Hoon Lee 1 , Yurii Ostapenko 1 , Pongwut Danchaivijitr 1 , Baogang Liu 1 , Adlinda Alip 1 , Ernesto Korbenfeld 1 , Josiane Mourão Dias 1 , Benjamin Besse 1 , Ki-Hyeong Lee 1 , Hailin Xiong 1 , Soon-Hin How 1 , Ying Cheng 1 , Gee-Chen Chang 1 , Hiroshige Yoshioka 1 , James C.-H. Yang 1 , Michael Thomas 1 , Danny Nguyen 1 , Sai-Hong I. Ou 1 , Sanjay Mukhedkar 1 , Kumar Prabhash 1 , Manolo D’Arcangelo 1 , Jorge Alatorre-Alexander 1 , Juan C. Vázquez Limón 1 , Sara Alves 1 , Daniil Stroyakovskiy 1 , Marina Peregudova 1 , Mehmet A.N. Şendur 1 , Ozan Yazici 1 , Raffaele Califano 1 , Vanesa Gutiérrez Calderón 1 , Filippo de Marinis 1 , Antonio Passaro 1 , Sang-We Kim 1 , Shirish M. Gadgeel 1 , John Xie 1 , Tao Sun 1 , Melissa Martinez 1 , Mariah Ennis 1 , Elizabeth Fennema 1 , Mahesh Daksh 1 , Dawn Millington 1 , Isabelle Leconte 1 , Ryota Iwasawa 1 , Patricia Lorenzini 1 , Mahadi Baig 1 , Sujay Shah 1 , Joshua M. Bauml 1 , S. Martin Shreeve 1 , Seema Sethi 1 , Roland E. Knoblauch 1 , Hidetoshi Hayashi 1
Affiliation
Amivantamab plus lazertinib (amivantamab–lazertinib) has shown clinically meaningful and durable antitumor activity in patients with previously untreated or osimertinib-pretreated EGFR (epidermal g...
中文翻译：
阿米万他单抗加拉泽替尼治疗既往未经治疗的 EGFR 突变晚期 NSCLC
阿米万他单抗联合拉泽替尼（阿米万他玛-拉泽替尼）在既往未经治疗或奥希替尼治疗过的 EGFR（表皮生长因子受体）患者中显示出具有临床意义和持久的抗肿瘤活性。
更新日期：2024-06-27
中文翻译：
阿米万他单抗加拉泽替尼治疗既往未经治疗的 EGFR 突变晚期 NSCLC
阿米万他单抗联合拉泽替尼（阿米万他玛-拉泽替尼）在既往未经治疗或奥希替尼治疗过的 EGFR（表皮生长因子受体）患者中显示出具有临床意义和持久的抗肿瘤活性。
京公网安备 11010802027423号